Senate Bill 252 Would Hike Health Care Costs for Alabama Patients, Families, and Employers by More Than $383 Million Every Year

Senate Bill 252 is a Big Pharma-backed proposal that would ban pay-for-performance incentives in the private health care marketplace—eliminating a key tool that employers use to lower prescription drug costs for hardworking Alabamans.

Instead of lowering the cost of prescription drugs, the bill undermines market-based savings, drives up insurance premiums and increases out-of-pocket costs for over 2.5 million Alabama residents who rely on employer for their health coverage.

Employers negotiate better deals on prescription drugs through voluntarily choosing to hire pharmacy benefit managers (PBMs), critical members of the health care system that pool their negotiating power to unlock savings for health plan sponsors, and the patients and families on these plans.

Senate Bill 252 would ban pay-for-performance incentives in the private health care marketplace that are essential for Alabama employers and their employees to secure significant savings on prescription drugs, directly leading to higher premium costs for patients.

These bills are not about protecting patients—they’re about protecting Big Pharma’s profits.